Long-term study of a weight-loss drug for trial graduates
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the main MARITIME-1 trial and its week 72 visit.
- You must not have stopped the study drug during the main trial.
- You must be able to start this extension within 7 days of your week 72 visit.
- You must not have a body mass index (BMI) lower than 18.5.
- You must use approved birth control during treatment and for 16 weeks after your last dose.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study compares two versions of an investigational weight-loss injection to see if they are absorbed similarly. It is an early-stage trial for adults with a BMI of 25 or higher who want to help improve future treatments.
This study tests whether people with obesity or overweight can safely and effectively give themselves the study medicine (called maridebart cafraglutide) at home using a pre-filled autoinjector pen. It is being studied as a weight-loss treatment for adults who have struggled to lose weight with diet and exercise alone.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.